Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Attovia looks to expand clinical development of its pipeline in 2027.
The post Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders appeared first on MedCity News.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
